JP2013531073A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013531073A5 JP2013531073A5 JP2013520841A JP2013520841A JP2013531073A5 JP 2013531073 A5 JP2013531073 A5 JP 2013531073A5 JP 2013520841 A JP2013520841 A JP 2013520841A JP 2013520841 A JP2013520841 A JP 2013520841A JP 2013531073 A5 JP2013531073 A5 JP 2013531073A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl group
- pharmaceutical composition
- substituted
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 150000001875 compounds Chemical class 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 6
- 102100028662 Sigma intracellular receptor 2 Human genes 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 101710109012 Sigma intracellular receptor 2 Proteins 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 4
- 125000004442 acylamino group Chemical group 0.000 claims 4
- 125000004423 acyloxy group Chemical group 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000003367 polycyclic group Chemical group 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 2
- 229940127236 atypical antipsychotics Drugs 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000027776 Extrapyramidal disease Diseases 0.000 claims 1
- 208000001613 Gambling Diseases 0.000 claims 1
- 208000004547 Hallucinations Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 206010021030 Hypomania Diseases 0.000 claims 1
- 206010021567 Impulsive behaviour Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 108010040167 sigma-2 receptor Proteins 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 CN1Cl(CN=C)c2c(*)c(*)c(*)c(CCC3CC3)c2C1=O Chemical compound CN1Cl(CN=C)c2c(*)c(*)c(*)c(CCC3CC3)c2C1=O 0.000 description 1
- RNRYULFRLCBRQS-UHFFFAOYSA-N O=C(CN1CCC(CN(Cc2c3cccc2)C3=O)CC1)c(cc1)ccc1F Chemical compound O=C(CN1CCC(CN(Cc2c3cccc2)C3=O)CC1)c(cc1)ccc1F RNRYULFRLCBRQS-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36608010P | 2010-07-20 | 2010-07-20 | |
| US61/366,080 | 2010-07-20 | ||
| PCT/US2011/044698 WO2012012543A1 (en) | 2010-07-20 | 2011-07-20 | Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016135208A Division JP2016199578A (ja) | 2010-07-20 | 2016-07-07 | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013531073A JP2013531073A (ja) | 2013-08-01 |
| JP2013531073A5 true JP2013531073A5 (OSRAM) | 2014-09-04 |
Family
ID=45497167
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013520841A Pending JP2013531073A (ja) | 2010-07-20 | 2011-07-20 | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 |
| JP2016135208A Pending JP2016199578A (ja) | 2010-07-20 | 2016-07-07 | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 |
| JP2017225061A Active JP6419294B2 (ja) | 2010-07-20 | 2017-11-22 | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016135208A Pending JP2016199578A (ja) | 2010-07-20 | 2016-07-07 | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 |
| JP2017225061A Active JP6419294B2 (ja) | 2010-07-20 | 2017-11-22 | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20130274290A1 (OSRAM) |
| EP (2) | EP4070794A3 (OSRAM) |
| JP (3) | JP2013531073A (OSRAM) |
| KR (1) | KR101867634B1 (OSRAM) |
| CN (2) | CN103108548A (OSRAM) |
| BR (1) | BR112013001302A2 (OSRAM) |
| CA (2) | CA2805904C (OSRAM) |
| DK (1) | DK2595485T3 (OSRAM) |
| ES (1) | ES2914120T3 (OSRAM) |
| HU (1) | HUE058736T2 (OSRAM) |
| PL (1) | PL2595485T3 (OSRAM) |
| PT (1) | PT2595485T (OSRAM) |
| RU (2) | RU2613201C2 (OSRAM) |
| TW (1) | TWI520949B (OSRAM) |
| WO (1) | WO2012012543A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8937900B2 (en) | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
| WO2015191554A1 (en) * | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| CA2968977A1 (en) * | 2014-12-02 | 2016-06-09 | Minerva Neurosciences, Inc. | Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
| SG11201810358YA (en) * | 2016-05-25 | 2018-12-28 | Mitsubishi Tanabe Pharma Corp | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
| EP3641732A1 (en) | 2017-06-21 | 2020-04-29 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
| WO2020041504A1 (en) * | 2018-08-21 | 2020-02-27 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| US20230190870A1 (en) | 2020-05-20 | 2023-06-22 | The Board Of Trustees Of The University Of Illinois | Method for Treating Lysosomal Storage Diseases with Histatin Peptides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE903857A1 (en) * | 1989-10-27 | 1991-05-08 | Du Pont Merck Pharma | (N-Phthalimidoalkyl)Piperidines |
| ZA908641B (en) * | 1989-10-27 | 1992-06-24 | Du Pont | (n-phthalimidoalkyl)piperidines |
| NZ251610A (en) * | 1992-04-23 | 1996-02-27 | Merrell Dow Pharma | 4-imidomethyl-1-(2-phenyl-2-oxoethyl)piperidine derivatives and pharmaceutical compositions |
| PT1260512E (pt) * | 2000-02-29 | 2007-10-10 | Mitsubishi Pharma Corp | ''novos derivados de amida cíclicos'' |
| TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
-
2011
- 2011-07-20 EP EP22162273.1A patent/EP4070794A3/en active Pending
- 2011-07-20 US US13/810,775 patent/US20130274290A1/en not_active Abandoned
- 2011-07-20 DK DK11810350.6T patent/DK2595485T3/da active
- 2011-07-20 HU HUE11810350A patent/HUE058736T2/hu unknown
- 2011-07-20 CA CA2805904A patent/CA2805904C/en active Active
- 2011-07-20 CA CA3154027A patent/CA3154027A1/en active Pending
- 2011-07-20 RU RU2013107378A patent/RU2613201C2/ru active
- 2011-07-20 TW TW100125662A patent/TWI520949B/zh active
- 2011-07-20 CN CN2011800450188A patent/CN103108548A/zh active Pending
- 2011-07-20 KR KR1020137004218A patent/KR101867634B1/ko active Active
- 2011-07-20 JP JP2013520841A patent/JP2013531073A/ja active Pending
- 2011-07-20 RU RU2017105262A patent/RU2746871C2/ru active
- 2011-07-20 CN CN201611063838.0A patent/CN107007603A/zh active Pending
- 2011-07-20 PL PL11810350T patent/PL2595485T3/pl unknown
- 2011-07-20 BR BR112013001302A patent/BR112013001302A2/pt not_active Application Discontinuation
- 2011-07-20 PT PT118103506T patent/PT2595485T/pt unknown
- 2011-07-20 WO PCT/US2011/044698 patent/WO2012012543A1/en not_active Ceased
- 2011-07-20 ES ES11810350T patent/ES2914120T3/es active Active
- 2011-07-20 EP EP11810350.6A patent/EP2595485B1/en active Active
-
2016
- 2016-05-24 US US15/163,385 patent/US20160354357A1/en not_active Abandoned
- 2016-07-07 JP JP2016135208A patent/JP2016199578A/ja active Pending
-
2017
- 2017-11-22 JP JP2017225061A patent/JP6419294B2/ja active Active
-
2020
- 2020-06-29 US US16/914,862 patent/US20210106573A1/en not_active Abandoned
-
2025
- 2025-01-15 US US19/021,774 patent/US20250228838A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013531073A5 (OSRAM) | ||
| CN111770914B (zh) | 作为神经激肽-1受体拮抗剂的化合物及其用途 | |
| JP2016528301A5 (OSRAM) | ||
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| JP2016517857A5 (OSRAM) | ||
| JP2016528162A5 (OSRAM) | ||
| JP2014528901A5 (OSRAM) | ||
| JP2015532296A5 (OSRAM) | ||
| RU2015143843A (ru) | Ингибиторы гистондеацетилазы | |
| JP2013522326A5 (OSRAM) | ||
| JP2015505564A5 (OSRAM) | ||
| JP2015536986A (ja) | 併用療法 | |
| JP2015536986A5 (OSRAM) | ||
| RU2014119711A (ru) | Трициклические соединения, композиции, содержащие указанные соединения, и их применения | |
| BRPI0506765A (pt) | composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP6419294B2 (ja) | シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法 | |
| JP2016199578A5 (OSRAM) | ||
| JP2016503010A5 (OSRAM) | ||
| JP2016512817A5 (OSRAM) | ||
| JP2016516792A (ja) | α−２アドレノレセプターおよびシグマレセプターリガンドの組み合わせ物 | |
| JP2017526693A5 (OSRAM) | ||
| RU2016116789A (ru) | Комбинация энзалутамида и афурезертиба для лечения рака | |
| JP2015522592A5 (OSRAM) | ||
| JP2016523830A5 (OSRAM) |